Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$0.36
EPS est.
$0.31
EPS surprise
+15.38%
1-day move
+4.02%
Baxter International's better-than-expected EPS indicates stronger profitability than analysts anticipated, which likely contributed to the stock's 4.02% increase. However, the lack of revenue data and guidance leaves some uncertainty about future performance. Investors may view the EPS beat positively, but the absence of further details could lead to cautious sentiment.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.36 | $0.32 | +15.38% |
| Revenue | N/A | $2.6B | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Baxter International Inc. is a healthcare company that specializes in medical equipment and supplies, focusing on areas such as renal care and hospital products. With a market cap of $9 billion, Baxter plays a crucial role in providing essential medical solutions that impact patient care and outcomes.
Last quarter
In Q4 2025, Baxter reported an EPS of $0.44, which was below analyst expectations of $0.53, leading to a significant drop in stock price. The company has faced challenges in meeting revenue targets, contributing to investor concerns.
EPS beat streak
2Q
EPS beat rate
63%
Avg EPS surprise
+11.39%
Avg 1-day reaction
-4.74%
Analysts expect Baxter to report an EPS of $0.32 and revenue of $2.6 billion for Q1 2026, reflecting cautious optimism amid recent performance struggles. Investors will be closely monitoring the company's ability to meet these expectations.
Bull case
If Baxter exceeds EPS and revenue estimates, it could signal a turnaround in performance, boosting investor confidence and potentially leading to a positive stock reaction.
Bear case
Conversely, if Baxter misses these estimates again, it may raise further concerns about its operational challenges and lead to a negative stock reaction.
Key metrics to watch
EPS
0.32Earnings per share is a key indicator of the company's profitability and performance.
Revenue
2.6BTotal revenue reflects the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Baxter's EPS meet or exceed the consensus estimate of $0.32?
Given the company's recent struggles, meeting or exceeding EPS expectations is crucial for restoring investor confidence.
Q2
What commentary will management provide on revenue growth and operational challenges?
Insights into revenue performance and operational strategies will be critical for understanding the company's future trajectory.
—
Est. EPS
$0.76
Est. Rev
$17.1B
Impl. Move
±2.9%
Why consensus could be wrong
The Street may be underestimating Baxter's potential for a rebound, given the recent operational adjustments and focus on core product lines.
Supporting evidence
Baxter has a history of beating EPS expectations 63% of the time, suggesting potential for positive surprises.
The options market is pricing a significant move, indicating that traders expect volatility that could favor a rebound.
Recent operational changes may not yet be fully reflected in analyst models, potentially leading to underestimated performance.
Key risk
If Baxter shows strong revenue growth in key segments, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as the company seeks to regain momentum after recent misses.
Bull confirmed if
Baxter needs to report an EPS of $0.32 or higher with revenue meeting or exceeding $2.6 billion to confirm a bullish outlook.
Bear confirmed if
An EPS below $0.26 or revenue below $2.5 billion would confirm a bearish outlook.
What the market is pricing for the move.
Implied Move
±9.53%
Historical Avg
±9.9%
The options market is pricing in a significant move of approximately 9.5% around the earnings report, indicating uncertainty among investors.
Options are pricing ±9.5% while BAX has averaged ±9.9% over the last 8 prints — setup is roughly in line with history.
ATM IV
1.6%
30d HV
38.7%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing in-line setup in Health Care
Fade rate: 12 of 27 (44%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 27 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 6.0%, with a raw directional average of +3.0% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
110.22%
of float
Insider
0.34%
of float
Holders
951
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
81,842,105 sh · $2.0B
15.83%
3.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Baxter beats expectations, history suggests a modest positive reaction, averaging around +1.9% on the following day.
In line / cautious
If results are in line with expectations, the stock may experience a muted response, reflecting ongoing investor caution.
Miss
Should Baxter miss expectations, history indicates a potential decline of around -14.1% in the stock price.
The lines on the call that would change the story.
Pzena Investment Management LLC
65,295,393 sh · $1.6B
12.63%
1.2%
Dodge & Cox Inc.
58,386,345 sh · $1.4B
11.29%
2.0%
FMR, LLC
53,913,831 sh · $1.3B
10.43%
16.5%
Vanguard Capital Management LLC
33,754,280 sh · $809.1M
6.53%
0.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.